Effect Of Umbilical Cord Mesenchymal Stem Cells And Amniotic Epithelial Cells In The Treatment Of Right Heart Failure Caused By Experimental Pulmonary Arterial Hypertension

Objective.This study was designed to investigate the efficacy of human umbilical cord mesenchymal stem cells(UC-MSCs)and human amniotic epithelial cells(AECs)in the treatment of PAH and right heart failure(RHF)by establishing a rat model of pulmonary arterial hypertension(PAH)induced by monocrotaline(MCT).Methods The experimental animals were divided into 4 groups(control group,PAH group,UC-MSCS group and AECS group).After 1 week of intraperitoneal injection of MCT,the UC-MSCS group was injected with UC-MSCS suspension by sublingual vein,the AECS group was injected with AECS suspension by sublingual vein,and the control group and PAH group were injected with the same amount of normal saline by sublingual vein.4 weeks later,right ventricular echocardiography,right ventricular catheterization manometry,right cardiac hypertrophy index and lung pathology were performed in rats.Results Compared with the control group,right ventricular free wall thickness(RVWT)and right ventricular inner diameter(RVID)were significantly increased in PAH group,the ratio of pulmonary artery acceleration time to ejection time(PAT/PET)was significantly decreased,right systolic pressure(RVSP)and right cardiac hypertrophy index(RVHI)were significantly increased,and pulmonary aorta wall thickness(WT)was significantly increased.Compared with PAH group,RVWT and RVID were significantly decreased,PAT/PET were significantly increased,RVSP and RVHI were significantly decreased,and WT was significantly thinner in UC-MSCS group and AECS group.Conclusion PAH rat model was successfully established by intraperitoneal injection of MCT.Both UC-MSCs and AECs can reverse pulmonary vascular remodeling,reduce pulmonary artery pressure,improve right ventricular function,and delay RHF by sublingual intravenous injection...